Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.

Authors
Type
Published Article
Journal
Diabetes Care
0149-5992
Publisher
American Diabetes Association
Publication Date
Volume
36
Issue
9
Pages
2536–2542
Identifiers
DOI: 10.2337/dc12-2329
PMID: 23715753
Source
Medline
License
Unknown

Abstract

In this treat-to-target trial in insulin-naïve patients with T2DM, IDeg 200 units/mL improved glycemic control similarly to IGlar with a low risk of hypoglycemia.

Statistics

Seen <100 times